Kolexia
Le Scodan Romuald Oncologie radiothérapie
Le Scodan Romuald
Oncologie radiothérapie
Clinique De La Cote D'emeraude
Saint-Malo, France
128 Activités
1.1 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Tumeurs du cerveau Récidive tumorale locale Carcinomes Maladie de Hodgkin Carcinome canalaire du sein Lymphomes Seconde tumeur primitive

Collaborateurs

Voir plus
Labib Alain
Labib Alain
Clcc Institut Curie, Paris, France
Kirov Youlia
Kirov Youlia
Clcc Institut Curie, Paris, France
Mercier-Blas Anne
Mercier-Blas Anne
C.h Fougeres, Fougères, France
Artignan Xavier
Artignan Xavier
Clinique De La Cote D'emeraude, Saint-Malo, France

Industries

Voir plus
Lilly
5 collaboration(s)
Dernière en 2022
MSD
3 collaboration(s)
Dernière en 2022
Pfizer
3 collaboration(s)
Dernière en 2023
Novartis
2 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
Essai Clinique (Lilly)   29 février 2024
Radiation therapy of the primary tumour and oligometastatic sites in patients with breast cancer with synchronous metastases: A literature review.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   07 décembre 2023
SAFIR 03: A ctDNA Screening Program in Patients With HR+, HER2- Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor and a Randomised Phase II Study Comparing Alpelisib Combined With Fulvestrant to Ribociclib Combined With Fulvestrant, in Patients With Persistent Targetable PIK3CA Mutations
Essai Clinique (Unicancer)   20 novembre 2023
RIBOLARIS: Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer
Essai Clinique (Novartis)   06 octobre 2023
OSCAR: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   16 août 2023
121TiP LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- early breast cancer at very low risk of metastasis
Abstract Book of ESMO Breast Cancer 2023, Berlin, Germany, 11-13 May 2023   01 mai 2023
167MO Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial
Abstract Book of ESMO Breast Cancer 2022, Berlin, Germany, 03-05 May 2022   01 mai 2022
LBA32 Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
Première étude randomisée, multicentrique, contrôlée en double insu, étudiant l'efficacité du sulforaphane versus placebo chez des patients atteints d'un cancer de la prostate en échappement biologique après prostatectomie totale±radiothérapie externe.
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie   30 octobre 2014
Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology   29 octobre 2014